Odimma Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
7
Odimma Therapeutics General Information
Description
Developer of an immunotherapy drug designed for personalized immunotherapy to treat cancer. The company's platform combines three specific immune players that synergize with the immune system when injected into patients to induce and amplify an immune response and cellular immune response against specific tumour markers, enabling patients to cure tumors with fewer side effects and support the cancer treatment.
Contact Information
Website
www.odimma-therapeutics.comCorporate Office
- ISIS, 8 Allée Gaspard Monge
- 67000 Strasbourg
- France
Corporate Office
- ISIS, 8 Allée Gaspard Monge
- 67000 Strasbourg
- France
Odimma Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 6. Later Stage VC | 11-Jul-2023 | Completed | Clinical Trials - Phase 1 | |||
| 5. Seed Round | 20-Oct-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Seed Round | 18-Dec-2019 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 18-Dec-2019 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Odimma Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| ABSA P2022 | ||||||||
| P Shares | ||||||||
| P Shares | 80,646 | $0.414654 | $6.77 | $6.77 | 1x | $6.77 | 18.12% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Odimma Therapeutics Comparisons
Industry
Financing
Details
Odimma Therapeutics Competitors (84)
One of Odimma Therapeutics’s 84 competitors is Amal Therapeutics, a Formerly VC-backed company based in Geneva, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amal Therapeutics | Formerly VC-backed | Geneva, Switzerland | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| MonTa BioSciences | Venture Capital-Backed | Lyngby, Denmark | ||||
| Repertoire Immune Medicines | Venture Capital-Backed | Cambridge, MA | ||||
| Immunophotonics | Private Equity-Backed | Saint Louis, MO |
Odimma Therapeutics Patents
Odimma Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026154072-A1 | Enveloped virus for transfection of exogenous nucleic acids | Pending | 17-Jan-2025 | ||
| FR-3171450-A1 | Enveloped virus for transfection of exogenous nucleic acids. | Pending | 17-Jan-2025 | ||
| FR-3160186-A1 | Non-viral vector for enhanced transcription | Pending | 13-Mar-2024 | ||
| WO-2025190971-A1 | Non-viral vector for enhanced transcription | Pending | 13-Mar-2024 | C12N15/85 |
Odimma Therapeutics Signals
Odimma Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alsace Business Angels | Angel Group | Minority | ||
| Angels Santé | Angel Group | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| Capital Grand Est | PE/Buyout | Minority | ||
| Matwin | Accelerator/Incubator |
Odimma Therapeutics FAQs
-
When was Odimma Therapeutics founded?
Odimma Therapeutics was founded in 2017.
-
Where is Odimma Therapeutics headquartered?
Odimma Therapeutics is headquartered in Strasbourg, France.
-
What is the size of Odimma Therapeutics?
Odimma Therapeutics has 4 total employees.
-
What industry is Odimma Therapeutics in?
Odimma Therapeutics’s primary industry is Biotechnology.
-
Is Odimma Therapeutics a private or public company?
Odimma Therapeutics is a Private company.
-
What is Odimma Therapeutics’s current revenue?
The current revenue for Odimma Therapeutics is .
-
How much funding has Odimma Therapeutics raised over time?
Odimma Therapeutics has raised $3.28M.
-
Who are Odimma Therapeutics’s investors?
Alsace Business Angels, Angels Santé, Bpifrance, Capital Grand Est, and Matwin are 5 of 7 investors who have invested in Odimma Therapeutics.
-
Who are Odimma Therapeutics’s competitors?
Amal Therapeutics, AnTolRx, MonTa BioSciences, Repertoire Immune Medicines, and Immunophotonics are some of the 84 competitors of Odimma Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process